Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Subcutaneous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bosnia | Brazil | Croatia | India | Ireland | Taiwan | Thailand | Turkey | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: M.D. Anderson Cancer Center
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Renal Transplant|Other
Phase 2: Pleural Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Amyotrophic Lateral Sclerosis|Acute Myeloid Leukemia|Hereditary Sensory and Autonomic Neuropathies|Peripheral Nervous System Diseases|Carcinoma, Merkel Cell|Alzheimer Disease|Myeloid, Accelerated Leukemia|Acute Monocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Megakaryoblastic Leukemia|Blast Crisis|Preleukemia|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Erythroblastic Leukemia|Chronic Myelomonocytic Leukemia|Pancreatic Cancer|Adenocarcinoma
Phase 1: Kidney Cancer|Renal Cell Carcinoma|Colorectal Cancer|Pancreatic Ductal Carcinoma|Melanoma|Pancreatic Cancer|Cervical Cancer|Sarcoma|Uterine Cancer|Adenocarcinoma|Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified|Stem Cell Transplant|Graft vs Host Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RR-DVIVO | P3 |
Unknown Status |
Renal Transplant |
2027-12-31 |
|
| NCI-2024-08121 | P1 |
Not yet recruiting |
Kidney Cancer|Pancreatic Ductal Carcinoma|Cervical Cancer|Melanoma|Colorectal Cancer|Renal Cell Carcinoma|Adenocarcinoma|Pancreatic Cancer|Uterine Cancer |
2027-10-30 |
|
| ChiCTR2400089707 | N/A |
Not yet recruiting |
Kidney Diseases |
2026-01-01 |
|
| SENSE | P2 |
Recruiting |
Hereditary Sensory and Autonomic Neuropathies |
2025-08-01 |